Abstract
In our efforts to identify potent CRF(1) antagonists with proper physicochemical properties, a series of 3-phenylpyrazolo[1,5-a]pyrimidines bearing polar groups, such as amino, hydroxyl, methoxy, sulfoxide, were designed and synthesized. Several positions of the core structure were identified, where a polar group was tolerated with slight reduction in receptor binding. NBI 30545 (18n) was found to have good binding affinity and potent antagonistic activity at the human CRF(1) receptor. Moreover, this compound had proper lipophilicity (log D = 2.78) and good solubility in water (>10mg/mL), and exhibited good plasma and brain exposure when given orally.
MeSH terms
-
Adrenocorticotropic Hormone / metabolism
-
Animals
-
Binding, Competitive
-
Brain / metabolism
-
Corticotropin-Releasing Hormone / pharmacology
-
Cyclic AMP / metabolism
-
Drug Design*
-
Plasma / metabolism
-
Pyrazoles / chemical synthesis
-
Pyrazoles / pharmacology*
-
Pyrimidines / chemical synthesis
-
Pyrimidines / pharmacology*
-
Rats
-
Rats, Sprague-Dawley
-
Receptors, Corticotropin-Releasing Hormone / antagonists & inhibitors*
-
Receptors, Corticotropin-Releasing Hormone / metabolism
-
Solubility
-
Structure-Activity Relationship
-
Water / chemistry
Substances
-
NBI 30545
-
Pyrazoles
-
Pyrimidines
-
Receptors, Corticotropin-Releasing Hormone
-
Water
-
CRF receptor type 1
-
Adrenocorticotropic Hormone
-
Corticotropin-Releasing Hormone
-
Cyclic AMP